NEW YORK, May 30, 2013 (GLOBE NEWSWIRE) -- Context Matters announces the addition of a solid tumor cancer module into its proprietary thin-client, cloud-based web application and data platform, the Reimbursement Risk Tracker™ (RRT), which provides pharmaceutical and biotechnology customers with unprecedented access to information for clinical development, drug reimbursement, regulatory considerations and pricing.
This new capability provides users the ability to cross-reference drugs across solid tumor disease states to allow a more nuanced understanding of the reimbursement and regulatory environment for these cancers. The module contains a newly introduced "tagging" system that allows users to identify specific oncological disease conditions and subsets that can be linked across disease conditions and adding another 25 different search variables to those currently offered in the RRT. As the product rolls out its hematology oncology module, the company expects to add even more.
"Our expansion into solid tumor disease conditions is in part a response to high client demand for information as broad and even deeper than what we provide in other therapeutic areas. And we designed this module in such a way as to provide the most complete picture possible within the oncology treatment environment, in which many drugs have multiple indications and higher scrutiny in terms of costs and reimbursement," said Yin Ho, MD, MBA, founder and CEO of Context Matters. "The development of this oncology module, and the modules to follow have also helped us to realize the potential improvements we can still make on our flagship product, allowing us to continue to offer both increasing breadth of information, but an incredible depth that is unprecedented in the industry right now."
The RRT helps users analyze more than 500 complex variables across more than 100 global sources of data. The web-based application delivers data and analysis directly to the users and provides a platform to ask unlimited questions about reimbursement risk through comparisons across multiple dimensions. Context Matters offers a scalable and flexible tool that allows users to relate and compare data sets – including data on orphan indications – that may have not been compared previously, all in a user-friendly product.
Context Matters, Inc. is the next generation of healthcare data analytics, focusing on risk assessment metrics for pharmaceutical and biotechnology products. Its data-driven /evidence-based approach begins with a proprietary software database platform of intelligently culled, curated, and relevant business information and data to answer strategic business questions and provide actionable analysis. Its platform and approach result in more informed decision-making by allowing users to access and understand complex data that has never before been quantified or aggregated through a tailored, needs-based approach.
Visit Context Matters at Booth #3049 at the ASCO Conference May 31st - June 4th at McCormick Place, Chicago or visit the website at www.contextmattersinc.com.
CONTACT: Jules Abraham JQA Partners, LLC (917) 885-7378 email@example.comSource: Context Matters